

**Supplementary Table 1: Correlation Between NDRG2 Expression and Clinicopathologic Parameters of Adenoid Cystic Carcinoma**


Characteristics	NDRG2 expression		<i>P</i> value
	high	low	
<b>Age, y</b>			<b>0.794</b>
≤55	<b>22</b>	<b>50</b>	
>55	<b>18</b>	<b>37</b>	
<b>Sex</b>			<b>0.21</b>
<b>Male</b>	<b>15</b>	<b>44</b>	
<b>Female</b>	<b>25</b>	<b>43</b>	
<b>Tumor site</b>			<b>0.261</b>
<b>Major glands</b>	<b>15</b>	<b>24</b>	
<b>Minor glands</b>	<b>25</b>	<b>63</b>	
<b>Histological grade</b>			<b>0.713</b>
<b>I-II</b>	<b>33</b>	<b>74</b>	
<b>III</b>	<b>7</b>	<b>13</b>	
<b>Perineural invasion</b>			<b>0.667</b>
<b>Yes</b>	<b>27</b>	<b>62</b>	
<b>No</b>	<b>13</b>	<b>25</b>	
<b>Recurrence</b>			<b>0.783</b>
<b>Yes</b>	<b>11</b>	<b>26</b>	
<b>No</b>	<b>29</b>	<b>61</b>	
<b>Distant metastasis</b>			<b>.000</b>
<b>Yes</b>	<b>7</b>	<b>63</b>	
<b>No</b>	<b>33</b>	<b>24</b>	

**Supplementary Table 2: primary antibodies used in this study**


Protein	Assay	Antibody
NDRG2	WB, IHC	sc-376202, Santa Cruz
MYB	WB	Ab-45150, Abcam
Stat3	WB	9139, CST
p-Stat3	WB	52075, CST
AKT	WB	4685s, CST
p-AKT	WB	4051, CST

**Supplementary Table 3: Sequences of primers, miRNA mimics, inhibitors and siRNAs**


Name	Sequences(5'-3')
hsa-miR-130a mimic	CAGUGCAAUGUUAAAAGGGCAU AUGCCCUUUAACAUUGCACUG
hsa-miR-181a inhibitor	ACUCACCGACAGCGUUGAAUGUU
hsa-miR-324a-3p inhibitor	CCAGCAGCACCUUGGGCAGUGGG
hsa-miR-130a inhibitor	AUGCCCUUUAACAUUGCACUG
mimic-control	UCACAACCUCUAGAAAGAGUAGA UCUACUCUUUCUAGGAGGUUGUGA
inhibitor-control	UCUACUCUUUCUAGGAGGUUGUGA
siMYB-1	AAAGUACUAAACCCUGAGC tt GCUCAGGGUUUAGUACUUU tt
siMYB-2	CAAUGUUCUCAAAGCAUUU tt AAAUGCUUUGAGAACAUUG tt
siMYB-3	CUUGGAAAUGCUCUUUA tt UAAAAGGAAGGCAUUUCCAAG tt
siRNA-control	UUCUCCGAACGUGUCACGUDdT ACGUGACACGUUCGGAGAAdTdT
Promoter-site-1-F	CAAGGAAAATGATGTCTTGAGC
Promoter-site-1-R	GGAGAGAGAACACACAAAGGCT
Promoter-site-2-F	AGAAGCAAGACTGGACAAACAC
Promoter-site-2-R	TTGGAGGATAAGGAGGGCAG
Promoter-site-3-F	TGGGCTGTCCATCTCTTG
Promoter-site-3-R	GAGCACACACATACATGTACATCAT
Promoter-site-4-F	ATTAAAAAGCCACTTCCTCAGTCAC
Promoter-site-4-R	CCTGATCTTGCAAGACTGTCATTAA
Promoter-site-5-F	CATCTAAACCCAAAGAATGGACC
Promoter-site-5-R	TGACCCCATACTACTCAGCCTAT
Promoter-site-6-F	GCATTTGTTGCAGCCCATA
Promoter-site-6-R	TAGCTGGCATCTGCTGGTTG




**Supplementary Figure 1:** Venn diagrams showing the number of total mapped miRNAs in both groups, the number of differentially expressed miRNAs and the three candidate miRNAs regulating NDRG2 in the two groups.




**Supplementary Figure 2:** The relative miR-130a levels in miR-130a over-expression cells and the control cells.



**Supplementary Figure 3:** The relative mRNA levels of NDRG2 in miR-130a over-expression cells and the control cells.



**Supplementary Figure 4:** the reduction of NDRG2 protein amounts in miR-130a-overexpressing cell lines.



**Supplementary Figure 5:** the relative expressions of MYB in tumors and the corresponding normal salivary gland of fresh samples.